OBJECTIVE: The purpose of this study was to examine the impact of prior authorization policies on the receipt of antipsychotic medication for Medicaid-enrolled children. METHODS: Using de-identified administrative Medicaid data from two large, neighboring, mid-Atlantic states from November 2007 through June 2011, we identified subjects <18 years of age using antipsychotics, from the broader group of children and adolescents receiving behavioral health services or any psychotropic medication. Prior authorization for antipsychotics was required for children in State A <6 years of age from September 2008, and for children <13 years of age from August 2009. No such prior authorizations existed in State B during that period. Filled prescriptions were identified in the data using national drug codes. Using a triple-difference strategy (using differences among the states, time periods, and differences in antidepressant prescribing rates among states over the same time periods), we examined the effect of the prior authorization policy on the rate at which antipsychotic prescriptions were filled for Medicaid-enrolled children and adolescents. RESULTS: The impact of prior authorization policies on antipsychotic medication use varied by age: Among 6-12 year old children, the impact of the prior authorization policy on antipsychotic medication prescribing was a modest but statistically significant decrease of 0.47% after adjusting for other factors; there was no effect of the prior authorization among children 0-5 years. CONCLUSIONS: Prior authorization policies had a modest but statistically significant effect on antipsychotic use in 6-12 year old children, but had no impact in younger children. Future research is needed to understand the utilization and clinical effects of prior authorization and other policies and interventions designed to influence antipsychotic use in children.
OBJECTIVE: The purpose of this study was to examine the impact of prior authorization policies on the receipt of antipsychotic medication for Medicaid-enrolled children. METHODS: Using de-identified administrative Medicaid data from two large, neighboring, mid-Atlantic states from November 2007 through June 2011, we identified subjects <18 years of age using antipsychotics, from the broader group of children and adolescents receiving behavioral health services or any psychotropic medication. Prior authorization for antipsychotics was required for children in State A <6 years of age from September 2008, and for children <13 years of age from August 2009. No such prior authorizations existed in State B during that period. Filled prescriptions were identified in the data using national drug codes. Using a triple-difference strategy (using differences among the states, time periods, and differences in antidepressant prescribing rates among states over the same time periods), we examined the effect of the prior authorization policy on the rate at which antipsychotic prescriptions were filled for Medicaid-enrolled children and adolescents. RESULTS: The impact of prior authorization policies on antipsychotic medication use varied by age: Among 6-12 year old children, the impact of the prior authorization policy on antipsychotic medication prescribing was a modest but statistically significant decrease of 0.47% after adjusting for other factors; there was no effect of the prior authorization among children 0-5 years. CONCLUSIONS: Prior authorization policies had a modest but statistically significant effect on antipsychotic use in 6-12 year old children, but had no impact in younger children. Future research is needed to understand the utilization and clinical effects of prior authorization and other policies and interventions designed to influence antipsychotic use in children.
Authors: Elizabeth Pappadopulos; Peter S Jensen; Sarah B Schur; James C MacIntyre; Scott Ketner; Kimberly Van Orden; Jeffrey Sverd; Sadhana Sardana; David Woodlock; Robert Schweitzer; David Rube Journal: Schizophr Bull Date: 2002 Impact factor: 9.306
Authors: Stephen B Soumerai; Fang Zhang; Dennis Ross-Degnan; Daniel E Ball; Robert F LeCates; Michael R Law; Tom E Hughes; Daniel Chapman; Alyce S Adams Journal: Health Aff (Millwood) Date: 2008-04-01 Impact factor: 6.301
Authors: Meredith Matone; Russell Localio; Yuan-Shung Huang; Susan dosReis; Chris Feudtner; David Rubin Journal: Health Serv Res Date: 2012-09-04 Impact factor: 3.402
Authors: Haiden A Huskamp; Marcela Horvitz-Lennon; Ernst R Berndt; Sharon-Lise T Normand; Julie M Donohue Journal: Psychiatr Serv Date: 2016-07-15 Impact factor: 3.084
Authors: Rebecca P Barclay; Robert B Penfold; Donna Sullivan; Lauren Boydston; Julia Wignall; Robert J Hilt Journal: Health Serv Res Date: 2017-04 Impact factor: 3.402
Authors: Kimberly Eaton Hoagwood; Susan Essock; Joseph Morrissey; Anne Libby; Sheila Donahue; Benjamin Druss; Molly Finnerty; Linda Frisman; Meera Narasimhan; Bradley D Stein; Jennifer Wisdom; Judy Zerzan Journal: Adm Policy Ment Health Date: 2016-01
Authors: Laura J Chavez; Kelly J Kelleher; Arne Beck; Gregory N Clarke; Robert B Penfold Journal: J Child Adolesc Psychopharmacol Date: 2021-06 Impact factor: 3.031